News for Coya Therapeutics Inc Stock (COYA)

Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer's Disease (AD) at the LD Micro Conference on June 7, 2023

Business Wire • 05/22/23

Coya: Outstanding Data In ALS And Alzheimer's Justify Large Upside

Seeking Alpha • 05/16/23

Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going

Zacks Investment Research • 05/16/23

Coya Therapeutics' COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer's Disease

Business Wire • 05/16/23

Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results

Business Wire • 05/10/23

Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET

Business Wire • 05/09/23

Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune Diseases

Seeking Alpha • 05/08/23

Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?

Accesswire • 04/14/23

Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023

Business Wire • 03/31/23

Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results

Business Wire • 03/29/23

Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

Business Wire • 03/27/23

Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET

Business Wire • 03/23/23

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

Zacks Investment Research • 03/21/23

Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET

Business Wire • 03/21/23

Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

Business Wire • 03/21/23

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

Business Wire • 03/20/23

Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET

Business Wire • 03/09/23

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

Business Wire • 02/27/23

Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya's Low-Dose Interleukin 2 (IL-2) Product Candidate

Business Wire • 02/15/23

Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023

Business Wire • 02/02/23

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer's Disease (AD)

Business Wire • 01/26/23

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering

Business Wire • 01/03/23

Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering

Business Wire • 12/29/22

IPO Update: Coya Therapeutics Readies $15 Million IPO

Seeking Alpha • 12/06/22

Coya Therapeutics Files For $22 Million IPO

Seeking Alpha • 12/01/22